AU2019271208B2 - Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis - Google Patents

Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis Download PDF

Info

Publication number
AU2019271208B2
AU2019271208B2 AU2019271208A AU2019271208A AU2019271208B2 AU 2019271208 B2 AU2019271208 B2 AU 2019271208B2 AU 2019271208 A AU2019271208 A AU 2019271208A AU 2019271208 A AU2019271208 A AU 2019271208A AU 2019271208 B2 AU2019271208 B2 AU 2019271208B2
Authority
AU
Australia
Prior art keywords
metarrestin
human
pancreatic adenocarcinoma
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019271208A
Other languages
English (en)
Other versions
AU2019271208A1 (en
Inventor
Michael Baltezor
John C BRAISTED
Christopher DEXTRAS
Marc Ferrer
John Haslam
Sui Huang
Serguei Kozlov
Juan Jose Marugan
Samarjit Patnaik
Udo RUDLOFF
Noel T Southall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
Northwestern University
US Department of Health and Human Services
Original Assignee
University of Kansas
Northwestern University
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas, Northwestern University, Government of the United States of America filed Critical University of Kansas
Publication of AU2019271208A1 publication Critical patent/AU2019271208A1/en
Application granted granted Critical
Publication of AU2019271208B2 publication Critical patent/AU2019271208B2/en
Priority to AU2025203402A priority Critical patent/AU2025203402A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
AU2019271208A 2018-05-15 2019-05-15 Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis Active AU2019271208B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203402A AU2025203402A1 (en) 2018-05-15 2025-05-12 Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671964P 2018-05-15 2018-05-15
US62/671,964 2018-05-15
PCT/US2019/032461 WO2019222380A1 (en) 2018-05-15 2019-05-15 Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203402A Division AU2025203402A1 (en) 2018-05-15 2025-05-12 Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis

Publications (2)

Publication Number Publication Date
AU2019271208A1 AU2019271208A1 (en) 2020-12-03
AU2019271208B2 true AU2019271208B2 (en) 2025-02-13

Family

ID=66691010

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019271208A Active AU2019271208B2 (en) 2018-05-15 2019-05-15 Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis
AU2025203402A Pending AU2025203402A1 (en) 2018-05-15 2025-05-12 Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025203402A Pending AU2025203402A1 (en) 2018-05-15 2025-05-12 Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis

Country Status (7)

Country Link
US (2) US20210186972A1 (https=)
EP (2) EP4721727A2 (https=)
JP (3) JP7421499B2 (https=)
AU (2) AU2019271208B2 (https=)
CA (1) CA3100211A1 (https=)
ES (1) ES3061722T3 (https=)
WO (1) WO2019222380A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3532464A4 (en) 2016-10-28 2020-07-08 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
CA3092677A1 (en) 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
CA3104298A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
CN118908962A (zh) 2019-05-06 2024-11-08 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
WO2022159650A1 (en) * 2021-01-22 2022-07-28 Icahn School Of Medicine At Mount Sinai HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2
US20260028342A1 (en) * 2022-07-29 2026-01-29 The University Of North Carolina At Chapel Hill Enhancing antimetastasis activity using targeted protein degradation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9877966B1 (en) * 2015-08-10 2018-01-30 Eugene J. Oliva Combination therapy for the inhibition of metastasis and tumorigenesis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2719803A1 (en) * 2008-03-28 2009-10-01 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
TR201905480T4 (tr) * 2008-04-18 2019-05-21 Angiochem Inc Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
EP2791142B1 (en) * 2011-12-16 2019-07-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis
TWI838700B (zh) * 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
US11241436B2 (en) * 2017-01-25 2022-02-08 Northwestern University Autophagy inducers for treatment of CNS conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9877966B1 (en) * 2015-08-10 2018-01-30 Eugene J. Oliva Combination therapy for the inhibition of metastasis and tumorigenesis

Also Published As

Publication number Publication date
JP2024050620A (ja) 2024-04-10
JP2021524844A (ja) 2021-09-16
US20210186972A1 (en) 2021-06-24
AU2025203402A1 (en) 2025-06-19
JP2026000929A (ja) 2026-01-06
JP7736825B2 (ja) 2025-09-09
US20240316056A1 (en) 2024-09-26
AU2019271208A1 (en) 2020-12-03
EP3793523B8 (en) 2026-01-21
ES3061722T3 (en) 2026-04-07
CA3100211A1 (en) 2019-11-21
AU2025203402A9 (en) 2026-03-05
EP3793523B1 (en) 2025-11-12
EP3793523A1 (en) 2021-03-24
WO2019222380A1 (en) 2019-11-21
JP7421499B2 (ja) 2024-01-24
EP4721727A2 (en) 2026-04-08

Similar Documents

Publication Publication Date Title
AU2019271208B2 (en) Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis
US20240043390A1 (en) Compositions and methods for treating cancer
US11377451B2 (en) Compositions and methods for treating cancer
EP2968379B1 (en) Etoposide prodrugs for use in targeting cancer stem cells
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
CN120475974A (zh) 阿森色替（azenosertib）在治疗癌症中的间歇性给药方案
JP2022519777A (ja) 処置誘導性の胃腸傷害を防止又は処置する方法
JP2016088919A (ja) イベルメクチン又はミルベマイシンｄを有効成分として含む抗癌剤
CN118846055A (zh) 蛋白磷酸酶2a抑制剂在制备用于治疗brca2基因突变型癌症药物中的用途
US20150045363A1 (en) Hedgehog Pathway Inhibition for Cartilage Tumor and Metachondromatosis Treatment
CN111346096B (zh) 一种用于预防或治疗胶质瘤的药物组合物
JP2024518509A (ja) Ｐａｒｐ阻害剤抵抗性癌治療剤
EA044668B1 (ru) Композиции и способы для лечения рака
EA049995B1 (ru) Соединения, ингибирующие изоформу альфа pi3k, и способы лечения онкологического заболевания
HK1220365B (en) Etoposide prodrugs for use in targeting cancer stem cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)